Compare EYPT & SOCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EYPT | SOCA |
|---|---|---|
| Founded | 1987 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.3M | 242.7M |
| IPO Year | 2005 | 2025 |
| Metric | EYPT | SOCA |
|---|---|---|
| Price | $0.37 | $10.39 |
| Analyst Decision | Hold | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $8.44 | N/A |
| AVG Volume (30 Days) | ★ 15.6M | 50.7K |
| Earning Date | 11-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $7,539,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $126.05 | N/A |
| P/E Ratio | ★ N/A | $173.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $10.01 |
| 52 Week High | $19.11 | $10.44 |
| Indicator | EYPT | SOCA |
|---|---|---|
| Relative Strength Index (RSI) | 17.21 | 55.20 |
| Support Level | N/A | $10.28 |
| Resistance Level | $3.57 | N/A |
| Average True Range (ATR) | 0.06 | 0.01 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 1.80 | 37.50 |
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Solarius Capital Acquisition Corp is a blank check company.